NO20063878L - Imidazo[1,2-c]pyrimidinyleddiksyrederivater - Google Patents
Imidazo[1,2-c]pyrimidinyleddiksyrederivaterInfo
- Publication number
- NO20063878L NO20063878L NO20063878A NO20063878A NO20063878L NO 20063878 L NO20063878 L NO 20063878L NO 20063878 A NO20063878 A NO 20063878A NO 20063878 A NO20063878 A NO 20063878A NO 20063878 L NO20063878 L NO 20063878L
- Authority
- NO
- Norway
- Prior art keywords
- diseases
- imidazo
- allergic
- acid derivative
- treatment
- Prior art date
Links
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- JELCUCXNEYEZOO-UHFFFAOYSA-N 2-imidazo[1,2-c]pyrimidin-2-ylacetic acid Chemical class C1=NC=CC2=NC(CC(=O)O)=CN21 JELCUCXNEYEZOO-UHFFFAOYSA-N 0.000 abstract 2
- 102000009389 Prostaglandin D receptors Human genes 0.000 abstract 2
- 108050000258 Prostaglandin D receptors Proteins 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 208000016557 Acute basophilic leukemia Diseases 0.000 abstract 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 abstract 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 201000004624 Dermatitis Diseases 0.000 abstract 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 abstract 1
- 102000011652 Formyl peptide receptors Human genes 0.000 abstract 1
- 108010076288 Formyl peptide receptors Proteins 0.000 abstract 1
- 108091006027 G proteins Proteins 0.000 abstract 1
- 102000030782 GTP binding Human genes 0.000 abstract 1
- 108091000058 GTP-Binding Proteins 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 210000004241 Th2 cell Anatomy 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 206010052568 Urticaria chronic Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 208000002205 allergic conjunctivitis Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000024998 atopic conjunctivitis Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 210000003651 basophil Anatomy 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000024376 chronic urticaria Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000003979 eosinophil Anatomy 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 abstract 1
- 206010024378 leukocytosis Diseases 0.000 abstract 1
- 230000000414 obstructive effect Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000009890 sinusitis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04002144 | 2004-01-31 | ||
| PCT/EP2005/000475 WO2005073234A2 (en) | 2004-01-31 | 2005-01-19 | Imidazo[1,2-c]pyrimidinylacetic acid derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20063878L true NO20063878L (no) | 2006-10-11 |
Family
ID=34814234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20063878A NO20063878L (no) | 2004-01-31 | 2006-08-31 | Imidazo[1,2-c]pyrimidinyleddiksyrederivater |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US7750014B2 (de) |
| EP (1) | EP1718649B1 (de) |
| JP (1) | JP4996257B2 (de) |
| KR (1) | KR101207428B1 (de) |
| CN (1) | CN100584844C (de) |
| AT (1) | ATE433452T1 (de) |
| AU (1) | AU2005209381B2 (de) |
| BR (1) | BRPI0507123A (de) |
| CA (1) | CA2551778C (de) |
| CY (1) | CY1109274T1 (de) |
| DE (1) | DE602005014849D1 (de) |
| DK (1) | DK1718649T3 (de) |
| ES (1) | ES2326896T3 (de) |
| IL (1) | IL177083A (de) |
| MX (1) | MXPA06007674A (de) |
| NO (1) | NO20063878L (de) |
| NZ (1) | NZ548396A (de) |
| PL (1) | PL1718649T3 (de) |
| PT (1) | PT1718649E (de) |
| RU (1) | RU2373208C2 (de) |
| SI (1) | SI1718649T1 (de) |
| WO (1) | WO2005073234A2 (de) |
| ZA (1) | ZA200605387B (de) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1833791T3 (pl) | 2004-12-27 | 2011-12-30 | Actelion Pharmaceuticals Ltd | Pochodne 2,3,4,9-tetrahydro-1H-karbazolu jako antagonisty receptora CRTH2 |
| KR101411820B1 (ko) | 2006-08-07 | 2014-06-24 | 액테리온 파마슈티칼 리미티드 | (3-아미노-1,2,3,4-테트라하이드로-9ｈ-카르바졸-9-일)-아세트산 유도체 |
| US20100048579A1 (en) * | 2007-04-13 | 2010-02-25 | Luca Arista | Pyridazine-, pyridine- and pyrane-derivatives as gpbar1 agonists |
| UA99138C2 (ru) * | 2007-06-21 | 2012-07-25 | Актимис Фармасьютикалз, Инк. | Частичка антагониста crth2 (варианты) |
| KR20100061746A (ko) * | 2007-09-25 | 2010-06-08 | 액티미스 파마수티컬스 인코포레이티드 | Ｃｒｔｈ２ 길항제로서의 ２－ｓ－벤질 치환된 피리미딘 |
| PT2205569E (pt) * | 2007-09-25 | 2012-05-25 | Actimis Pharmaceuticals Inc | Alquiltiopirimidinas como antagonistas de crth2 |
| WO2009102893A2 (en) | 2008-02-14 | 2009-08-20 | Amira Pharmaceuticals, Inc. | CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 receptors |
| WO2009145989A2 (en) | 2008-04-02 | 2009-12-03 | Amira Pharmaceuticals, Inc. | Aminoalkylphenyl antagonists of prostaglandin d2 receptors |
| WO2010027448A1 (en) * | 2008-09-02 | 2010-03-11 | Actimis Pharmaceuticals Inc. | Isotopically enriched pyrimidin-5-yl acetic acid derivatives as crth2 antagonists |
| WO2010057118A2 (en) | 2008-11-17 | 2010-05-20 | Amira Pharmaceuticals, Inc. | Heterocyclic antagonists of prostaglandin d2 receptors |
| WO2011117798A1 (en) | 2010-03-22 | 2011-09-29 | Actelion Pharmaceuticals Ltd | 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators |
| JP5800898B2 (ja) | 2010-07-05 | 2015-10-28 | アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | １−フェニル−置換ヘテロシクリル誘導体及びプロスタグランジンｄ２受容体調節剤としてのそれらの使用 |
| DE102011003315A1 (de) | 2011-01-28 | 2012-08-02 | Bayer Schering Pharma Aktiengesellschaft | Annellierte Pyrimindine und Triazine und ihre Verwendung |
| DE102010031149A1 (de) | 2010-07-09 | 2012-01-12 | Bayer Schering Pharma Aktiengesellschaft | Annellierte Pyrimidine und Triazine und ihre Verwendung |
| PH12013500055A1 (en) | 2010-07-09 | 2017-08-23 | Bayer Ip Gmbh | Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases |
| US8927559B2 (en) | 2010-10-11 | 2015-01-06 | Merck Sharp & Dohme Corp. | Quinazolinone-type compounds as CRTH2 antagonists |
| EP2457900A1 (de) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | Neue Pyrazolderivate mit CRTH2-antagonistischem Verhalten |
| MY165623A (en) | 2011-04-14 | 2018-04-18 | Idorsia Pharmaceuticals Ltd | 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
| SG11201402796SA (en) | 2011-12-16 | 2014-06-27 | Atopix Therapeutics Ltd | Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis |
| RU2014129613A (ru) | 2011-12-21 | 2016-02-10 | Актелион Фармасьютиклз Лтд | Гетероциклильные производные и их применение в качестве модуляторов рецептора простагландина d2 |
| DE102012200349A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung |
| DE102012200360A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte Triazine und ihre Verwendung |
| JP6140738B2 (ja) | 2012-03-06 | 2017-05-31 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 置換アザ二環およびその使用 |
| US9169270B2 (en) | 2012-07-05 | 2015-10-27 | Actelion Pharmaceuticals Ltd. | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators |
| HRP20181555T1 (hr) | 2014-03-17 | 2018-11-30 | Idorsia Pharmaceuticals Ltd | Derivati azaindol-octene kiseline i njihova uporaba kao modulatora receptora prostaglandina d2 |
| RU2016140708A (ru) | 2014-03-18 | 2018-04-18 | Идорсиа Фармасьютиклз Лтд | Производные азаиндол уксусной кислоты и их применение в качестве модуляторов рецептора простагландина d2 |
| PL3350179T3 (pl) | 2015-09-15 | 2021-08-02 | Idorsia Pharmaceuticals Ltd | Krystaliczne postacie |
| KR20190103507A (ko) | 2018-02-12 | 2019-09-05 | 김강민 | 지하철 혼잡도 알림 시스템 |
| WO2019139462A2 (ko) * | 2019-02-21 | 2019-07-18 | 엘지전자 주식회사 | 하차 시점 알림 방법 및 사용자 단말 |
| TW202100015A (zh) | 2019-02-28 | 2021-01-01 | 瑞士商先正達農作物保護公司 | 具有含硫取代基之殺有害生物活性雜環衍生物 |
| CN118141793A (zh) * | 2022-05-17 | 2024-06-07 | 中国医学科学院基础医学研究所 | 二甲双胍及其它含胍化合物溶解夏科-莱登结晶并缓解急性肺损伤炎症中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE790679A (fr) | 1971-11-03 | 1973-04-27 | Ici Ltd | Derives de l'indole |
| GB9125842D0 (en) | 1991-12-04 | 1992-02-05 | Ici Plc | Heterocyclic derivatives |
| MXPA01007019A (es) * | 1999-11-10 | 2002-09-18 | Johnson & Johnson | 2-aril-3-(heteroaril)-imidazo[1,2-a]pirimidinas, sustituidas y composiciones farmaceuticas relacionados y metodos. |
| JP2001302667A (ja) * | 2000-04-28 | 2001-10-31 | Bayer Ag | イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体 |
| US6878522B2 (en) | 2000-07-07 | 2005-04-12 | Baiyong Li | Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2 |
| EP1413306A1 (de) | 2002-10-21 | 2004-04-28 | Warner-Lambert Company LLC | Tetrahydrochinolin-Derivate als CRTH2 Antagonisten |
| AU2003297398B2 (en) * | 2002-12-20 | 2009-09-24 | Amgen Inc. | Asthma and allergic inflammation modulators |
| ATE316077T1 (de) * | 2003-04-25 | 2006-02-15 | Actimis Pharmaceuticals Inc | Pyrimidin-essigsäure derivate geeignet zur behandlung von crth2-bedingten krankheiten |
-
2005
- 2005-01-19 NZ NZ548396A patent/NZ548396A/en not_active IP Right Cessation
- 2005-01-19 WO PCT/EP2005/000475 patent/WO2005073234A2/en not_active Ceased
- 2005-01-19 ES ES05706922T patent/ES2326896T3/es not_active Expired - Lifetime
- 2005-01-19 SI SI200530724T patent/SI1718649T1/sl unknown
- 2005-01-19 PL PL05706922T patent/PL1718649T3/pl unknown
- 2005-01-19 JP JP2006550019A patent/JP4996257B2/ja not_active Expired - Fee Related
- 2005-01-19 DE DE602005014849T patent/DE602005014849D1/de not_active Expired - Lifetime
- 2005-01-19 AU AU2005209381A patent/AU2005209381B2/en not_active Ceased
- 2005-01-19 CA CA2551778A patent/CA2551778C/en not_active Expired - Fee Related
- 2005-01-19 DK DK05706922T patent/DK1718649T3/da active
- 2005-01-19 AT AT05706922T patent/ATE433452T1/de active
- 2005-01-19 PT PT05706922T patent/PT1718649E/pt unknown
- 2005-01-19 US US10/585,429 patent/US7750014B2/en not_active Expired - Fee Related
- 2005-01-19 MX MXPA06007674A patent/MXPA06007674A/es active IP Right Grant
- 2005-01-19 RU RU2006131304/04A patent/RU2373208C2/ru not_active IP Right Cessation
- 2005-01-19 CN CN200580010462A patent/CN100584844C/zh not_active Expired - Fee Related
- 2005-01-19 ZA ZA200605387A patent/ZA200605387B/en unknown
- 2005-01-19 BR BRPI0507123-2A patent/BRPI0507123A/pt not_active IP Right Cessation
- 2005-01-19 EP EP05706922A patent/EP1718649B1/de not_active Expired - Lifetime
-
2006
- 2006-07-25 IL IL177083A patent/IL177083A/en not_active IP Right Cessation
- 2006-08-29 KR KR1020067017478A patent/KR101207428B1/ko not_active Expired - Fee Related
- 2006-08-31 NO NO20063878A patent/NO20063878L/no not_active Application Discontinuation
-
2009
- 2009-08-06 CY CY20091100834T patent/CY1109274T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200605387B (en) | 2008-05-28 |
| JP4996257B2 (ja) | 2012-08-08 |
| KR20060130187A (ko) | 2006-12-18 |
| DE602005014849D1 (de) | 2009-07-23 |
| CN100584844C (zh) | 2010-01-27 |
| KR101207428B1 (ko) | 2012-12-04 |
| US20090012102A1 (en) | 2009-01-08 |
| SI1718649T1 (sl) | 2009-10-31 |
| CY1109274T1 (el) | 2014-07-02 |
| EP1718649B1 (de) | 2009-06-10 |
| BRPI0507123A (pt) | 2007-06-19 |
| DK1718649T3 (da) | 2009-08-24 |
| IL177083A (en) | 2011-10-31 |
| EP1718649A2 (de) | 2006-11-08 |
| HK1101969A1 (en) | 2007-11-02 |
| ES2326896T3 (es) | 2009-10-21 |
| WO2005073234A3 (en) | 2005-10-06 |
| RU2006131304A (ru) | 2008-03-10 |
| CA2551778A1 (en) | 2005-08-11 |
| MXPA06007674A (es) | 2006-09-04 |
| PT1718649E (pt) | 2009-08-06 |
| NZ548396A (en) | 2010-06-25 |
| WO2005073234A2 (en) | 2005-08-11 |
| PL1718649T3 (pl) | 2009-11-30 |
| AU2005209381B2 (en) | 2011-06-30 |
| US7750014B2 (en) | 2010-07-06 |
| IL177083A0 (en) | 2006-12-10 |
| AU2005209381A1 (en) | 2005-08-11 |
| CN1938310A (zh) | 2007-03-28 |
| JP2007519659A (ja) | 2007-07-19 |
| CA2551778C (en) | 2013-10-22 |
| RU2373208C2 (ru) | 2009-11-20 |
| ATE433452T1 (de) | 2009-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1109274T1 (el) | Παραγωγα ιμιδαζο[1,2-c] πυριμιδινυλοξικου οξεος | |
| TW200505873A (en) | Pyrimidine derivatives | |
| EP2380891B1 (de) | Substituierte Piperidino-Dihydrothienopyrimidine | |
| WO2004011427A3 (en) | Substituted benzanilides as modulators of the ccr5 receptor | |
| WO2004010943A3 (en) | Substituted benzanilides as modulators of the ccr5 receptor | |
| NO996490L (no) | Substituerte benzanilider som CCR5-reseptorligander, anti- inflammatoriske midler og antivirale midler | |
| MXPA05010055A (es) | Derivados de 2-fenoxi- y 2-fenil-sulfomamida con actividad antagonista del ccr3, para el tratamiento del asma y otros desordenes inflamatorios o inmunologicos. | |
| JO3041B1 (ar) | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية | |
| BR0314830A (pt) | Derivados de azol-pirimidina fundida | |
| EA201170251A1 (ru) | ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 1,2,3,4-ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛ-3-ИЛ)УКСУСНОЙ КИСЛОТЫ, ПРИМЕНИМЫЕ В ЛЕЧЕНИИ АУТОИММУННЫХ И ВОСПАЛИТЕЛЬНЫХ РАССТРОЙСТВ | |
| MY157036A (en) | 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin d2 receptor antagonists | |
| ATE424402T1 (de) | Imidazopyridinverbindungen | |
| EA201100079A1 (ru) | Производные триазоло[4,5-d]пирамидина и их применение в качестве антагонистов пуринового рецептора | |
| NO20091489L (no) | Tiazolpyrazolopyridiner som CRF1 reseptorantagonister | |
| NZ595307A (en) | Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use | |
| EA200802417A1 (ru) | Замещенные фенилуксусные кислоты как dp-2-антагонисты | |
| BRPI0409393A8 (pt) | composto, composição farmacêutica, e, métodos para modulação de atividade de receptor de quimiocina em um mamífero, para tratamento, melhora, controle ou redução do risco de um distúrbio ou doença inflamatório e imunorregulatório, e de artrite reumatóide | |
| JP2015517587A5 (de) | ||
| WO2004010942A3 (en) | Substituted heterocyclic compounds as modulators of the ccr5 receptor | |
| NO20082297L (no) | Piperazinderivater som er anvendelige som CCR5-antagonister | |
| DE60011997D1 (de) | SUBSTITUIERTE BENZO(1,2-b:5,4-b')DIPYRAN-4-AMINE ALS CCR5 MODULATOREN | |
| MX2010003178A (es) | Primidinas sustituidas con 2-s-bencilo como antagonistas de crth2. | |
| Xia et al. | Substituted dipiperidine alcohols as potent CCR2 antagonists | |
| DE602006016244D1 (de) | Diazaspiro-ä4,4ü-nonanderivate als neurokinin-(nk1)-antagonisten | |
| TW200640910A (en) | Piperidinyl piperazine derivatives useful as inhibitors of chemokine receptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |